Side-by-side · Research reference
GonadorelinvsIGF-DES
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AFDA-ApprovedHUMAN-REVIEWED7/61 cited
BAnimal-StrongHUMAN-REVIEWED8/60 cited
Gonadorelin
GnRH Analogue · Diagnostic & Therapeutic
IV / SQ · Pulsatile Pump (Therapeutic) · Single Bolus (Diagnostic)
IGF-DES
IGF-1 Analogue · Truncated N-Terminal
~10×Potency vs IGF-1
ReducedIGFBP binding
ResearchStatus
Injection (local or systemic) · Research protocols onlyBredehöft 2008
01Mechanism of Action
Parameter
Gonadorelin
IGF-DES
Pathway
GnRH → Pituitary gonadotrope → LH/FSH secretion → Gonadal steroidogenesisSharma 2026
IGF1R activation → PI3K/Akt & MAPK signaling → protein synthesis, proliferation
Downstream effect
Pulsatile LH/FSH release stimulates testicular testosterone or ovarian estradiol/progesterone synthesis; initiates folliculogenesis and spermatogenesisRobin 2026Sharma 2026
Enhanced muscle protein synthesis, myoblast differentiation, reduced apoptosis, cell proliferation
Feedback intact?
Yes — pulsatile delivery preserves negative feedback loops; continuous exposure desensitizes receptors
Unknown — no human endocrine feedback data
Origin
Synthetic decapeptide (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) identical to native hypothalamic GnRH
Synthetic truncation of native IGF-1 — removal of N-terminal Gly-Pro-Glu tripeptideBredehöft 2008
Antibody development
—
—
02Dosage Protocols
Parameter
Gonadorelin
IGF-DES
Diagnostic test (pituitary function)
100 mcg IV or SQ bolus
Measure baseline LH/FSH, then 30/60/90 min post-injection. Normal response: LH ≥2× baseline.
—
Therapeutic (hypothalamic hypogonadism)
5–20 mcg IV bolus every 90–120 minutes
Requires portable pulsatile pump. Dose individualized to achieve normal gonadotropin pulsatility.Robin 2026
—
Pulsatile interval
90 minutes (females) · 120 minutes (males)
Mimics physiological GnRH pulse frequency.
—
Route
IV preferred (therapeutic) · SQ acceptable (diagnostic)
Subcutaneous or intramuscular (local injection favored)
Local delivery maximizes tissue-specific uptake.
Duration
Continuous until pregnancy achieved or fertility goals met
3–6 month courses typical for ovulation induction.
—
Evidence basis
RCT / Expert consensus
Animal models + in vitro only
Half-life
2–4 minutes (plasma)
Necessitates frequent pulsatile administration.
Shorter than IGF-1 due to reduced IGFBP binding
Rapid tissue uptake, limited systemic circulation.
Alternative protocols
Exogenous gonadotropins (hCG/hMG) often preferred due to convenience vs pump requirement
—
Research dose range
—
10–100 ng/mL (in vitro); μg doses (animal models)
Highly context-dependent; no standardized human protocol.
Frequency
—
Variable — daily to multiple times daily in research
Human data
—
None — no clinical trials
03Metabolic / Fat Loss Evidence
Parameter
Gonadorelin
IGF-DES
Fat loss mechanism
None — gonadorelin acts exclusively on reproductive axis
—
Indirect metabolic effects
Restoration of sex hormones may normalize body composition in hypogonadal states
Effect mediated by downstream testosterone/estradiol, not GnRH itself.
—
Primary mechanism
—
Indirect via muscle hypertrophy → metabolic rate elevation
Direct lipolysis
—
Minimal evidence — IGF-1 axis primarily anabolic, not lipolytic
Prostate model
—
Inhibited BPH cell proliferation when combined with vitamin D3 analogueCrescioli 2002
Context-specific anti-proliferative effect, not fat loss.
04Side Effects & Safety
Parameter
Gonadorelin
IGF-DES
Injection site reaction
Erythema, irritation (pulsatile pump catheter site)
Expected — erythema, irritation, local swelling
Headache
Common with bolus administration
—
Nausea / abdominal discomfort
Transient, dose-related
—
Ovarian hyperstimulation syndrome (OHSS)
Risk with ovulation induction protocols; monitor follicular development via ultrasound
—
Multiple gestation
Increased risk with fertility protocols (twins ~10–15%)
—
Anaphylaxis
Rare hypersensitivity reaction
—
Pump malfunction / infection
Mechanical failure or catheter-site infection with long-term IV pump use
—
Receptor desensitization
Continuous (non-pulsatile) exposure paradoxically suppresses gonadotropinsRobin 2026
—
Hypoglycemia risk
—
Theoretical — IGF-1 axis enhances glucose uptake
Mitogenic risk
—
Chronic IGF-1 receptor activation may promote cell proliferation, potential tumor growthCrescioli 2002
Edema / Fluid retention
—
Possible via sodium retention (IGF-1 axis effect)
Human safety data
—
Absent — no human trials, all effects theoretical or extrapolated
Unknown long-term effects
—
No chronic dosing studies in humans; endocrine, metabolic consequences unknown
Absolute Contraindications
Gonadorelin
- ·Pregnancy (except therapeutic infertility protocols)
- ·Hypersensitivity to gonadorelin or excipients
- ·Hormone-dependent tumors (prostate, breast) — risk of tumor stimulation via sex hormone elevation
IGF-DES
- ·Active malignancy or history of cancer (mitogenic risk)
- ·Pregnancy / lactation (no safety data)
- ·Hypoglycemia disorders
Relative Contraindications
Gonadorelin
- ·Ovarian cysts or PCOS (monitor for OHSS)
- ·Pituitary adenoma or other sellar mass (may worsen with gonadotropin surge)
IGF-DES
- ·Diabetes mellitus (unpredictable glucose effects)
- ·Renal or hepatic impairment (clearance unknown)
- ·Edema-prone conditions (heart failure, nephrotic syndrome)
05Administration Protocol
Parameter
Gonadorelin
IGF-DES
1. Diagnostic protocol
Administer 100 mcg IV or SQ bolus. Draw baseline LH/FSH, then at 30, 60, 90 minutes. Normal response: LH ≥2× baseline, FSH modest rise. Blunted response suggests pituitary pathology; exaggerated response may indicate primary hypogonadism.
Des(1-3)IGF-1 has no approved human protocol. All administration details are derived from animal or in vitro research and should not be construed as medical guidance.
2. Therapeutic pump setup (pulsatile)
Requires programmable infusion pump with IV catheter. Set pulse interval to 90 min (females) or 120 min (males). Bolus dose 5–20 mcg per pulse. Pump worn continuously; catheter site rotated every 48–72 hrs to prevent infection.
Sterile water or bacteriostatic water per research protocol. Gently swirl; do not shake. Store reconstituted peptide at 2–8 °C.
3. Reconstitution
Lyophilised gonadorelin reconstituted with sterile saline or provided diluent. Typically 0.8–3.2 mg dissolved in 8 mL for pump reservoir. Solution stable 7–14 days refrigerated.
Subcutaneous (abdomen, thigh) or intramuscular (deltoid, vastus lateralis). Local injection to target tissue (e.g., muscle group) may enhance regional uptake.
4. Monitoring
For fertility protocols: ultrasound follicular tracking + serial estradiol/LH measurements. Adjust pulse dose to achieve mid-follicular LH 5–10 IU/L. Ovulation confirmed by progesterone rise or ultrasound.
Frequency and timing vary by research design. Post-exercise or fasted state may theoretically enhance muscle uptake.
5. Timing
Pulsatile therapy initiated at any point in cycle. Diagnostic test performed in morning (higher baseline LH). For ovulation induction, treatment begins early follicular phase.
27–31G insulin syringe for subcutaneous; 25–27G for intramuscular.
6. Monitoring
—
Glucose monitoring essential (hypoglycemia risk). No established IGF-1 or safety labs for human use.
06Stack Synergy
Gonadorelin
+ hCG (Human Chorionic Gonadotropin)
Multi-pathwayIn hypogonadotropic hypogonadism protocols, gonadorelin restores pituitary LH/FSH pulsatility, while exogenous hCG directly stimulates Leydig cells (acting as LH mimetic) to maintain testosterone production. This dual approach ensures both central axis restoration and immediate gonadal steroidogenesis, preventing testicular atrophy during fertility treatment. hCG's longer half-life (24–36 hrs) complements gonadorelin's pulsatile short-acting profile.
- Gonadorelin
- 5–10 mcg IV every 120 min (pulsatile pump)
- hCG
- 1500–2000 IU SQ · 2–3× per week
- Duration
- 12–24 weeks for spermatogenesis induction
- Primary benefit
- Fertility restoration in hypothalamic hypogonadism with maintained testicular function
IGF-DES
+ BPC-157
ModerateDes(1-3)IGF-1 promotes myoblast differentiation and protein synthesis, while BPC-157 enhances tissue repair, angiogenesis, and collagen synthesis. Both act on distinct pathways (IGF1R vs gastric pentadecapeptide mechanisms) to support muscle recovery and connective tissue integrity. Synergy is mechanistic but lacks direct co-administration studies.
- Des(1-3)IGF-1
- Research dose post-workout (local IM)
- BPC-157
- 250–500 mcg SQ, daily or twice daily
- Frequency
- Daily or per research protocol
- Primary benefit
- Accelerated muscle repair, enhanced hypertrophy, connective tissue support
+ TB-500
ModerateTB-500 (Thymosin Beta-4 fragment) promotes cell migration, angiogenesis, and wound healing via actin regulation. Des(1-3)IGF-1 drives protein synthesis and myoblast proliferation. Combined, these peptides may synergistically enhance muscle recovery, repair, and hypertrophy through complementary anabolic and regenerative pathways. No direct human co-administration data.
- Des(1-3)IGF-1
- Research dose post-workout (local IM)
- TB-500
- 2–5 mg SQ, 2× weekly
- Frequency
- Per research cycle
- Primary benefit
- Muscle hypertrophy, injury recovery, vascular support